International consensus on the clinical management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer research program 10th anniversary conference

Research output: Contribution to journalArticlepeer-review


  • Naoto T. Ueno
  • Jose Rodrigo Espinosa Fernandez
  • Massimo Cristofanilli
  • Beth Overmoyer
  • Mohamad El-Shinawi
  • Jennifer Bellon
  • Huong T. Le-Petross
  • Anthony Lucci
  • Gildy Babiera
  • Sarah M. DeSnyder
  • Mediget Teshome
  • Edward Chang
  • Bora Lim
  • Savitri Krishnamurthy
  • Michael C. Stauder
  • Simrit Parmar
  • Mona M. Mohamed
  • Angela Alexander
  • Vicente Valero
  • Wendy A. Woodward

External organisations

  • Northwestern University
  • The University of Texas MD Anderson Cancer Center
  • Dana-Farber Cancer Institute
  • Ain Shams University
  • Department of Zoology, Faculty of Science, Cairo University


National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas. A consensus on the clinical management of patients with IBC was discussed, summarized, and subsequently reviewed. All participants at the conference (patients, advocates, researchers, trainees, and clinicians) were queried using the MDRing electronic survey on key management issues. A summary of the expert consensus and participant voting is presented. Bilateral breast and nodal evaluation, breast magnetic resonance imaging, positron emission tomography/computed tomography, and medical photographs were endorsed as optimal. Neoadjuvant systemic therapy, modified radical mastectomy and level I and II ipsilateral axillary node dissection, post-mastectomy radiotherapy, adjuvant targeted therapy and hormonal therapy as indicated, and delayed reconstruction were agreed-upon fundamental premises of standard non-protocol-based treatment for IBC. Consideration for local-regional therapy in de novo stage IV IBC was endorsed to provide local control whenever feasible. Variation across centers and special circumstances were discussed.


Original languageEnglish
Pages (from-to)1437-1447
Number of pages11
JournalJournal of Cancer
Issue number8
Publication statusPublished - 6 Apr 2018


  • BCS, Inflammatory breast cancer, Management, Mastectomy, Neoadjuvant chemotherapy, Radiation

ASJC Scopus subject areas

Sustainable Development Goals